Nanoparticles are useful for increasing drug stability, solubility, and availability. The small molecule baicalein inhibits fibrillation, and detoxifies aggregates of α‐synuclein (αSN) associated with Parkinson's disease (PD), but it suffers from instability, low solubility and consequent low availability. Here it is demonstrated that incorporation of baicalein into zwitterionic nanoliposomes (NLP‐Ba) addresses these problems. NLP‐Ba inhibits αSN fibril initiation, elongation, secondary nucleation, and also depolymerizes mature fibrils more effectively than free baicalein and prevents soluble αSN aggregates from seeding new fibrils. Importantly, NLP‐Ba perturbs oligomers’ capacity to permeabilize the membrane. The interaction between NLP‐Ba and αSN is confirmed by different biophysical techniques. This nanosystem crosses the blood‐brain barrier in vitro and is effective against rotenone neurotoxicity in vivo. The effect of NLP‐Ba on αSN fibrillation/cytotoxicity is attributed to a combination of free baicalein and empty NLPs. The results indicate a neuroprotective role for NLP‐Ba in decreasing αSN pathogenicity in PD and highlight the use of nanoliposomes to mobilize poorly soluble hydrophobic drugs.
20 February 2013 in Molecular Reproduction and Development
Differentiation therapy is attracting increasing interest in cancer as it can be more specific than conventional chemotherapy approaches, and it has offered new treatment options for some cancer types, such as treating acute promyelocytic leukaemia (APL) by retinoic acid. However, there is a pressing need to identify additional molecules which act in this way, both in leukaemia and other cancer types. In this work, we hence developed a novel transcriptional drug repositioning approach, based on both bioinformatics and cheminformatics components, that enables selecting such compounds in a more informed manner. We have validated the approach for leukaemia cells, and retrospectively retinoic acid was successfully identified using our method. Prospectively, the anti-parasitic compound fenbendazole was tested in leukaemia cells, and we were able to show that it can induce the differentiation of leukaemia cells to granulocytes in low concentrations of 0.1 μM and within as short a time period as 3 days. This work hence provides a systematic and validated approach for identifying small molecules for differentiation therapy in cancer.
In the current study, the effects of 7-BIO as a specific GSK3β inhibitor was examined on cell survival and expression of miR-29a-3p and miR-34a-5p in neurotoxin MPP+ treated SH-SY5Y cells. Our findings revealed that while co-treatment of the cells with 7-BIO and MPP+ did not alter the toxicity induced by MPP+, pretreatment with 3.5 μM 7-BIO for 6 h increased the survival of the 2 mM MPP+ treated cells. Also, qRT-PCR analysis of gene expression showed that while miR-29a-3p was unchanged in cells treated with either 2 mM MPP+ or 3.5 μM 7-BIO alone, miR-34a-5p was increased by MPP+ but decreased by 7-BIO. Pretreatment with 3.5 μM 7-BIO prior to MPP+ however, increased miR-29a-3p but decreased miR-34a-5p induced by MPP+. We therefore suggest that 7-BIO inhibition of GSK3β alleviates the MPP+ induced neurotoxicity by regulating miR-29a-3p and miR-34a-5p expressions in Parkinson's disease model SH-SY5Y cells.